恩替卡韦抗病毒治疗乙型肝炎肝硬化失代偿期的临床价值

The clinical value of entecavir antiviral treatment of hepatitis B with decompensated cirrhosis

目的探讨恩替卡韦抗病毒治疗乙型肝炎肝硬化失代偿期的临床价值。方法选择2015年1月至2020年1月在我院诊治的100例乙型肝炎肝硬化失代偿期患者作为研究对象,采用随机数字表法将入选患者均等划分为观察组及对照组,每组各50例。对照组采用拉米夫定予以治疗,观察组采用恩替卡韦予以抗病毒治疗,对比两组各项肝功能指标和治疗3个月、6个月后的HBV-DNA转阴率以及不良反应发生情况。结果观察组的TBIL、ALT、AST肝功能指标均低于对照组,差异有统计学意义(P<0.05),观察组的ALB高于对照组,差异有统计学意义(P<0.05)。观察组治疗3个月、6个月后的HBV-DNA转阴率均高于对照组,差异有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论乙型肝炎肝硬化失代偿期采用恩替卡韦抗病毒治疗,能够改善患者的肝功能,并可实现疗效的提升,且具备较高的安全性,值得推广。

Objective To explore the clinical value of entecavir antiviral treatment for hepatitis B with decompensated cirrhosis.Methods A total of 100 patients with decompensated hepatitis B liver cirrhosis diagnosed and treated in our hospital from January 2015 to January 2020 were selected as the research objects and equally divided into the observation group and the control group,with 50 cases in each group.The control group was treated with lamivudine,and the observation group was treated with entecavir.The liver function indexes,the negative conversion rate of HBV-DNA after 3 and 6 months of treatment,and the occurrence of adverse reactions were compared between the two groups.Results The TBIL,ALT and AST in the observation group were lower than those in the control group,ALB in the observation group was higher than that in the control group,with significant difference(P<0.05).The negative conversion rate of HBV-DNA in the observation group after three months and six months of treatment were higher than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Entecavir antiviral therapy in hepatitis B with decompensated cirrhosis can improve the liver function and curative effect of patients and has high safety,which is worthy of promotion.